Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
Portola Pharmaceuticals, Inc.announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola received $50 million at closing and may receive an additional $100 million upon U.S. Food and Drug Administration (FDA) approval of AndexXaTM (andexanet alfa) in exchange for a tiered, mid-single-digit royalty based on worldwide sales of the agent. The agreement is subject to a maximum total royalty payment of 195 percent of the $150 million funded by HCR, at which time the agreement would expire.

[adsense:336x280:8701650588]
- Read more about Doctor population ratio is 1:1668 in India
According to information provided by the Medical Council of India, there are a total of 9,88,922 allopathic doctors registered with the state medical council or MCI as of June 30, 2016.
- Read more about Medical Devices Rules, 2017 notify by Union health ministry
The Union health ministry has notified the Medical Devices Rules, 2017. The rules will come into effect from January 1, 2018. This rule has been introduced for the first time in the world.
- Read more about Ferring Pharmaceuticals and Enteris BioPharma joined to produce an Oral Formulation of a Peptide-based Injectable Therapeutic
Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced that the companies have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.
- Read more about Cytokinetics to sell Royalty on heart failure drug
Cytokinetics, Inc and Royalty Pharma announced that Cytokinetics has agreed to sell to Royalty Pharma a portion of the potential royalty due to Cytokinetics from Amgen on worldwide sales of omecamtiv mecarbil. Cytokinetics has also agreed to exercise its option to co-invest with Amgen in the Phase 3 development program of omecamtiv mecarbil in exchange for increased royalties from Amgen on worldwide sales of omecamtiv mecarbil outside Japan and co-promotion rights.
- Read more about Zydus acquired US based Sentynl Therapeutics
Zydus Cadila, a leading global healthcare provider announced that it has acquired Sentynl Therapeutics Inc., a US based specialty pharma company specialized in marketing of products in the pain management segment. The transaction will be EPS accretive. With this acquisition, Zydus makes a foray into the specialty pain market in the US valued at $ 8 billion.
- Read more about NPPA publish revised guidelines to halt scheduled formulations production under para 21 (2) of DPCO, 2013
NPPA issues revised internal guidelines on discontinuation of production of scheduled formulations under paragraph 21 (2) of the DPCO, 2013.
- Read more about Impact of Budget 2017 scheme on pharma sector
The life sciences sector had high expectations of the budget not only from the point of view of tax incentives, but also from a regulatory point of view. Expectations were based on the Government's vision of making India one of the top three pharmaceutical markets by 2020. This year too, no specific impetus was given to the sector.
- Read more about Health organization call on government of India to urgently put in place anti-tuberculosis drugs
Tuberculosis is without doubt a deadly disease that requires serious and constant attention. To address the growing incidence of drug-resistant tuberculosis, its survivors and various public health groups have written to the Department of Health for the incorporation of the patented drug Delamanid into the RNTCP(Revised National Tuberculosis Control Programme). Delamanid has been shown to be effective in the treatment of drug-resistant TB. In a letter to the Union Ministry of Health, the organizations urged the government to order Ostuka Pharmaceuticals Co. Ltd. (Otsuka), the company holding the drug monopoly, to register the delamanid in India without further delay.
- Read more about Health Ministry move to Supreme Court to challenges the revocation of the drug ban by FDC
The health ministry asked the Supreme Court to challenge an order of the Delhi High Court that had quashed its ban on more than 300 fixed-dose drugs. The health ministry last year had banned 344 FDCs, estimated to affect about 6,000 drug brands and shave over Rs 3,000 crore on the Indian pharmaceutical market, which is estimated to be over Rs 100,000 crore.

[adsense:336x280:8701650588]